Powerful
Versamune®
Platform

Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum.

LEARN MORE

Novel
Combination
Products

Our robust pipeline of promising cancer treatments is aimed at improving current cancer treatments by combining our products with FDA-approved standard of care and with other promising, clinical-stage immunotherapeutic agents.

LEARN MORE

World
Renowned
Partners

We have partnered with some of the world’s leading research institutions and pharmaceutical companies to develop more effective Versamune®-based cancer therapies and infectious disease vaccines to save lives.

LEARN MORE

Featured Publications

Peer Reviewed Publications
ASCO American Society of Clinical Oncology
Journal for ImmunoTherapy of Cancer
The Journal of Immunology

Company Presentations

Versamune®: A New Generation
of Cancer Immunotherapies

PDS0101: Interim Data for the Treatment of HPV-Associated Cancers

2021 Oncology R&D Day

Latest News


Versamune® Mechanism of Action Video

About Us

PDS Biotech is a clinical stage biopharmaceutical company with a growing pipeline of cancer immunotherapies and infectious disease vaccines. Our team is committed to developing first-in-class T-cell activating immunotherapies and preventive vaccines based on the Versamune platform to fight against cancer and infectious diseases.

Download corporate presentation >>

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf